Global Regenerative Medicine Market [By Technology – Cell Therapy, Tissue Engineering & Gene Therapy; By Region – North America (The US), Europe (The UK) & Asia Pacific (Japan) Market Outlook 2025

May 2019 | 74 pages | ID: GAE9D2FA03CEN
Rockville Research

Abstracts

Utilization of nanomaterial for tissue generation has created avenues for new realm of advancement in the field of regenerative medicine. It has facilitated control of biochemical and mechanical microenvironment for successful cell delivery and tissue regeneration especially in wound care, drug delivery, and immunomodulation.

The report “Global Regenerative Medicine Market [By Technology – Cell Therapy, Tissue Engineering & Gene Therapy; By Region – North America (The US), Europe (The UK) & Asia Pacific (Japan) Market Outlook 2025” provides in-depth analysis of the current scenario, detailed market outlook of the global regenerative medicine market overall as well as across various therapies such as Cell Therapy, Gene Therapy and Tissue Engineering. Regional analysis is done across major markets in North America, Europe and Asia Pacific.

The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities in global regenerative medicine market. The report has been segmented as following:-

Geographical Coverage

• North America – The US
• Europe – The UK
• Asia Pacific – Japan

Key Vendors

• Integra LifeSciences Corporation
• Merck & Co., Inc.
• Stryker Corporation
• Organogenesis Inc.
• Vericell Corporation
• MiMedx Group

Contents

1. EXECUTIVE SUMMARY

2. RESEARCH METHODOLOGY

3. REGENERATIVE MEDICINE

3.1 Overview
  3.1.1 Mechanism of Action
3.2 Therapies
  3.2.1 Cell Therapy
  3.2.2 Tissue Engineering
  3.2.3 Gene Therapy
  3.2.4 Small Molecule

4. MARKET ANALYSIS

4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
  4.2.1 Market Share by Therapy
  4.2.2 Market Share by Material
  4.2.3 Market Share by Therapeutic Application
  4.2.4 Market Share by End-User
  4.2.5 Market Share by Region

5. MARKET SEGMENTATION

5.1 Cell Therapy
  5.1.1 Market Sizing (Actual & Forecasted)
  5.1.2 Market Share by Region
5.2 Tissue Engineering
  5.2.1 Market Sizing (Actual & Forecasted)
  5.2.2 Market Share by Region
5.3 Gene Therapy
  5.3.1 Market Sizing (Actual & Forecasted)
  5.3.2 Market Share by Application
  5.3.3 Market Share by Region

6. REGIONAL ANALYSIS

6.1 North America
  6.1.1 Market Sizing (Actual &Forecasted)
  6.1.2 The US
    6.1.2.1 Market Sizing (Actual & Forecasted)
    6.1.2.1 Market Share by End-User
6.2 Europe
  6.2.1 Market Sizing (Actual &Forecasted)
  6.2.2 The UK
    6.2.2.1 Market Sizing (Actual & Forecasted)
    6.2.2.2 Market Share by Product Type
6.3 Asia Pacific
  6.3.1 Market Sizing (Actual &Forecasted)
  6.3.2 Japan
    6.3.2.1 Market Sizing (Actual & Forecasted)

7. MARKET DYNAMICS

7.1 Industry Trends & Developments
  7.1.1 Dominance of Dermatology Segment
  7.1.2 Adoption of 3D Bioprinting
  7.1.3 Use of Nanomaterial for Tissue Regeneration
  7.1.4 Higher Investments in Niche Therapies
7.2 Growth Drivers
  7.2.1 Prevalence of Chronic Diseases
  7.2.2 Rise in Number of Trauma Cases
  7.2.3 Organ Shortages
  7.2.4 Increasing Incidence of Cancer
  7.2.5 Growing Geriatric Population
  7.2.6 Increasing R&D Investment
7.3 Challenges
  7.3.1 Expensive Treatment Cost
  7.3.2 Stringent Regulatory Compliance

8. COMPETITIVE LANDSCAPE

8.1 Financial Analysis
8.2 Market Share Analysis

9. COMPANY PROFILES

9.1 Integra LifeSciences Corporation
9.2 Merck & Co., Inc.
9.3 Stryker Corporation
9.4 Organogenesis Inc.
9.5 Vericell Corporation
9.6 MiMedx Group, Inc.